2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 403

Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis
Abstract Number: 2803

Methotrexate Impacts the Effects of Tofacitinib, but Not Tocilizumab, on Clinically Relevant Biomarkers in Human Primary Cell–Based BioMAP^® Disease Models: Can We Utilize in Vitro Models to Predict Clinical Outcomes?
Abstract Number: 2792

Methotrexate Prevents Inflammatory Osteolysis By Activation of the Adenosine a_2A Receptor (A2AR)
Abstract Number: 514

Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis
Abstract Number: 1469

Methotrexate Treatment Reduces Serum IL-6 Level By Decreasing a CD14brightCD16+ Intermediate Non-Classical Subset of Monocytes in RA Patients
Abstract Number: 1716

MHC Class I and Class II Genes Influence Systemic Sclerosis Susceptibility, Clinical Presentation and Autoantibody Profile in a Mexican Admixed Population
Abstract Number: 2744

Mi-RNA Profile of Active Vascular BEHÇET’S Patients
Abstract Number: 88

Microbiomes of Inflammatory and Non-Inflammatory Thoracic Aortic Aneurysms
Abstract Number: 2740

Microbiota Modulate Intraepithelial Lymphocyte Presence and Function
Abstract Number: 1689

Microhaemorrages and Giant Capillaries in Nailfold Videocapillariscopies Are Able to Accurately Predict Disease Activity Level in Systemic Sclerosis
Abstract Number: 2748

Microparticles May Play a Role in Causing Thrombosis in Behçet’s Syndrome and Act As a Biomarker for Risk Management
Abstract Number: 2174

MicroRNA-146a in Salivary Gland Epithelial Cells Inhibits Co-Stimulatory Molecule CD80 Expression and Increases Autoreactive T Cell Activation in Sjögren’s Syndrome
Abstract Number: 999

Microrna-155 As an Epigenetic Regulator of B-Cell Activation in Rheumatoid Arthritis: In Vivo and in Vitro Evidences
Abstract Number: 2737

Microrna-155 Suppresses IL-21 Signaling and Production in Systemic Lupus Erythematosus
Abstract Number: 2449

Microrna-346 Regulation of Follicular Helper T Cells Is Involved in the Pathogenesis of rheumatoid Arthritis Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].